⚡ Thunder Equity Research

AbbVie Inc. (ABBV) Stock Analysis: Financial Performance & Investment Outlook for 2025

📅 March 13, 2025 ABBV Healthcare ⏱️ 1 min read 👁️ 2 views

Dive into AbbVie Inc. (ABBV) stock analysis with detailed financials, dividend insights, and forecasts. Learn about its strong portfolio, cash flow, growth drivers, and challenges like Humira erosion and high debt. Is ABBV a good investment for 2025?

📊 Interactive stock chart for ABBV available in the full interactive version

AbbVie Inc. (ABBV) Stock Analysis: Financial Performance & Investment Outlook for 2025

Overview of AbbVie Inc. (ABBV): A Biopharmaceutical Leader

AbbVie Inc. (ticker: ABBV) is a global biopharmaceutical powerhouse with a revenue of approximately $57.37 billionin FY 2024. Known for its dominance in immunology with drugs like Humira, Skyrizi, and Rinvoq, AbbVie continues to be a key player in the pharmaceutical industry.

Get Full Analysis & Investment Recommendations

Access detailed financial models, price targets, and actionable investment insights. Join over 500 equity research reports.

Access Thunder Equity Research Platform

Topics:

ABBV stockAbbVie stock priceABBV dividendABBV stock forecastAbbVie earningsAbbVie stock analysisIs ABBV a good investmentAbbVie pipelinebiopharmaceutical stocks